A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)

Status: Open to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT04289779

Abstracts/Posters/Presentations:

• D Kilari, A Szabo, KA Bylow, RS Alter, AA Nelson, E Lemke, WA Hall, S Johnson, P Langenstroer, K Jacobsohn, NB Davis, C Fung, MI Milowsky. A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study. Presented as a Trials in Progress Poster at the ASCO 2021 Annual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr TPS4591). See abstract.

• M Milowsky, N Davis, C Fung, S Johnson, P Langenstroer, K Jacobsohn, K Bylow, D Kilari. A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE). Presented as a Trials in Progress E-Poster at the ESMO 2020 Virtual Congress, Sept. 17, 2020. Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274. See abstract.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.